November 6, 2012 | Unnecessary trial endpoints are a waste of clinical trials budget, finds a study released by the Tufts Center for the Study of Drug Development. Nearly one out of every five procedures performed during later stage clinical trials – or more precisely, 18 percent – collect extraneous data and cost drug developers $1.1 million per trial. Pharmalot